Abbott Labs Stock Price, News & Analysis

Abbott (NYSE: ABT) announced the launch of TEAM-HF, a groundbreaking clinical trial aimed at improving outcomes for advanced heart failure patients. The study will enroll up to 850 patients across 75 sites worldwide, using Abbott's CardioMEMS™ HF System to monitor pulmonary artery pressures and identify patients who could benefit from early HeartMate 3™ left ventricular assist device intervention. The trial addresses a critical gap in heart failure treatment, as approximately 6.7 million Americans have heart failure, with numbers expected to reach 8.5 million by 2030. The study's primary and secondary endpoints will be evaluated at two years, with follow-up through five years.

Abbott (NYSE:ABT) and the Big Ten Conference have launched 'The We Give Blood Drive,' a first-ever conference-wide blood donation competition. Running from Sept. 26 through Dec. 6, the initiative aims to address critical U.S. blood shortages by engaging 18 member schools' students, alumni, and fans. The school generating the most donations will receive a $1 million grant for student or community health, announced at the Big Ten Championship Game on Dec. 7. Participants receive a free one-month B1G+ streaming subscription and entry to win championship game tickets. The competition addresses declining younger donor numbers and aims to ensure a stable blood supply.

Abbott and Abbott Fund are responding to the devastation caused by Hurricanes Helene and Milton in the southeastern United States. Working with disaster relief partners like Feeding America, Direct Relief, Americares, and World Central Kitchen, they're providing aid to affected communities in Florida, Georgia, North Carolina, and Tennessee.

The company's proactive approach included pre-positioning 'disaster relief packs' with nutrition and medical products at food banks and health clinics. Additional donations of Ensure, PediaSure, Glucerna, Pedialyte, Similac, and diabetes care products have been made to meet immediate needs. Abbott Fund is also providing grants to support basic necessities and medical care in the aftermath of Hurricane Milton.

Abbott reported third-quarter 2024 results with sales of $10.6 billion, driven by strong underlying base business performance. Reported sales growth was 4.9%, with organic sales growth for the underlying base business at 8.2%, led by double-digit growth in Medical Devices. Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales. The company raised its full-year adjusted diluted EPS guidance to $4.64 to $4.70. Abbott's board authorized a new $7 billion share repurchase program. Notable developments include a partnership with Medtronic for continuous glucose monitoring, the U.S. launch of Lingo™, and completion of enrollment in the VOLT-AF IDE trial for the Volt™ Pulsed Field Ablation System.

Abbott (NYSE: ABT) announced significant progress in its pulsed field ablation (PFA) solutions for electrophysiology. The company completed enrollment ahead of schedule in the VOLT-AF IDE Study for the Volt™ PFA System and launched the global FOCALFLEX trial for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™. These studies advance two Abbott PFA catheters for treating atrial fibrillation (AFib).

Additionally, Abbott received FDA clearance for the Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, supporting mapping of PFA and radiofrequency ablation cases. The Volt PFA System pairs a balloon-in-basket catheter with Abbott's EnSite™ X EP System for improved heart mapping. The TactiFlex Duo Ablation Catheter offers both PFA and RF energy delivery with a flexible tip for precise targeting.

These advancements aim to overcome limitations of early-generation PFA systems and provide physicians with more options for treating AFib patients.

Abbott (NYSE: ABT) and the Big Ten Conference are launching 'The We Give Blood Drive', a first-of-its-kind nationwide blood donation competition among 18 Big Ten universities. The initiative aims to address the critical blood shortage in the U.S. and inspire younger donors. The competition runs from Sept. 26 to Dec. 6, 2024, with the winner announced at the Big Ten Championship Game on Dec. 7.

Key points:

• The school with the most blood donations wins a $1 million donation from Abbott for student or community health
• Participants receive a free one-month B1G+ streaming subscription and a chance to win tickets to the Big Ten Football Championship Game
• Donation totals will be tracked live at BigTen.Org/Abbott
• Abbott becomes the health sciences and diagnostics partner of the Big Ten Conference

Abbott (NYSE: ABT) has announced that it will release its third-quarter 2024 financial results on Wednesday, October 16, before the market opens. Following the announcement, the company will host a live webcast of its earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors and interested parties can access the webcast through Abbott's Investor Relations website at www.abbottinvestor.com. For those unable to attend the live event, an archived edition of the call will be made available later the same day.

Abbott (NYSE: ABT) has declared its 403rd consecutive quarterly dividend of 55 cents per share. The dividend will be payable on Nov. 15, 2024, to shareholders of record as of Oct. 15, 2024. This announcement marks a significant milestone in Abbott's history of consistent dividend payments since 1924.

The company has demonstrated a remarkable track record of increasing its dividend payout for 52 consecutive years. This achievement has earned Abbott a place in the prestigious S&P 500 Dividend Aristocrats Index, which recognizes companies that have raised their dividends annually for at least 25 consecutive years.

Abbott's 2023 Global Sustainability Report highlights progress towards its 2030 Sustainability Plan goals, focusing on expanding health access and improving lives globally. Key achievements include:

1. Introducing the world's first dual-chamber leadless pacemaker system, expanding access to millions.
2. Partnering with mAbxience to increase access to biosimilar medicines in emerging markets.
3. Expanding emergency medicine reach to 1.3 million people in Tanzania.
4. Achieving a 7% reduction in Scope 1 and 2 carbon emissions.
5. Reducing overall water use by 3% and certifying four sites with Alliance for Water Stewardship.
6. Increasing sites with zero waste to landfill to 53 globally.
7. Doubling goals for creating development and job opportunities, including STEM programs for young people.

Abbott continues to integrate sustainability principles across its business to innovate for greater access and affordability in healthcare.